or Try an Advanced Search...

    Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 11.83 -2.07% -0.25
    YMAB closed down 2.07 percent on Monday, July 1, 2024, on approximately normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical YMAB trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Calm After Storm Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    20 DMA Support Bullish -2.07%
    Bollinger Band Squeeze Range Contraction -2.07%
    Wide Range Bar Range Expansion -2.07%
    BB Squeeze + Upper Band Touch Range Contraction -2.07%
    Outside Day Range Expansion -2.07%
    Older End-of-Day Signals for YMAB ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 7 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    20 DMA Resistance about 9 hours ago
    10 DMA Resistance about 9 hours ago
    Down 1% about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    YMAB Chart by TradingView
    Basic chart:

    Profile

    Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Cancer Treatment Blastoma Therapeutic Products Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

    Is YMAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 10 With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest
    Jun 7 Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
    Jun 5 Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
    Jun 1 Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
    Jun 1 Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
    May 9 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
    May 9 Y-mAbs: There's A Ceiling Here Somewhere
    May 9 Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
    May 9 Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
    May 8 Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript
    See more YMAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.9
    52 Week Low 4.6
    Average Volume 351,855
    200-Day Moving Average 10.56
    50-Day Moving Average 13.13
    20-Day Moving Average 12.06
    10-Day Moving Average 12.00
    Average True Range 0.63
    RSI (14) 42.20
    ADX 12.63
    +DI 24.72
    -DI 14.13
    Chandelier Exit (Long, 3 ATRs) 11.18
    Chandelier Exit (Short, 3 ATRs) 13.41
    Upper Bollinger Bands 12.49
    Lower Bollinger Band 11.63
    Percent B (%b) 0.23
    BandWidth 7.14
    MACD Line -0.24
    MACD Signal Line -0.32
    MACD Histogram 0.0839
    Fundamentals Value
    Market Cap 516.04 Million
    Num Shares 43.6 Million
    EPS -0.45
    Price-to-Earnings (P/E) Ratio -26.29
    Price-to-Sales 6.16
    Price-to-Book 5.71
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.66
    Resistance 3 (R3) 12.73 12.52 12.52
    Resistance 2 (R2) 12.52 12.31 12.49 12.47
    Resistance 1 (R1) 12.18 12.18 12.08 12.11 12.43
    Pivot Point 11.97 11.97 11.92 11.94 11.97
    Support 1 (S1) 11.63 11.76 11.53 11.56 11.23
    Support 2 (S2) 11.42 11.63 11.39 11.19
    Support 3 (S3) 11.08 11.42 11.14
    Support 4 (S4) 11.01